Skip to content

MapLight Therapeutics, Inc. MPLT Proceeds From Exercises Of Stock Options And Employee Stock Purchase Plan Issuances

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B+100%
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept mplt:ProceedsFromExercisesOfStockOptionsAndEmployeeStockPurchasePlanIssuances.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's proceeds from exercises of stock options and employee stock purchase plan issuances.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's proceeds from exercises of stock options and employee stock purchase plan issuances?
MapLight Therapeutics, Inc. (MPLT) reported proceeds from exercises of stock options and employee stock purchase plan issuances of $651K in Q1 2026.